Table 1: Cases distribution for sex, age and suspected drug
|
1. |
Table 2: Medications reported as responsible of Pityriasi Rosea-like eruptions
Medication |
Main References |
• ACE-inhibitors |
• Wilkin JK, et al. Arch Dermatol 1980; 116: 902-5. • Steckelings UM, et al. Acta Derm Venereol 2001; 81: 321-5. • Wilkin JK, et al. Arch Dermatol 1982; 118: 186-7. • Ghersetich I, et al. G Ital Dermatol Venereol 1990; 125: 457-9. • Atzori L, et al. J Eur Acad Dermatol Venereol 2004; 18: 743-5. |
• NSAIDs |
• Corke CF, et al. Br J Rheumatol 1983; 22: 187-8. • Yosipovitch G, et al. Harefuah 1993; 124: 198-200. • Wolf R, et al. Dermatologica 1985; 171: 355-6. |
• Omeprazole |
• Buckley C. Br J Dermatol 1996; 135: 660-1. |
• Metronidazole |
• Maize JC, et al. Arch Dermatol 1977; 113: 1457-8. |
• Isotretinoin |
• Helfman RJ, et al. Cutis 1984; 33: 297-300. |
• Gold salts |
• Bonnetblanc JM. Presse Med 1996; 25: 1555-8. |
• Imatinib mesylate |
• Konstantopoulos K, et al. Dermatology 2002; 205: 172-3. |
Interferon • |
• Durusoy C, et al. J Dermatol 1999; 26: 225-8. |
• Arsenic compounds • Barbiturates • Bismuth • Beta-blockers • Clonidine • Griseofulvin • Meprobamate • Penicillin |
• Stulberg DL, et al. Am Fam Physician 2004; 69: 87-92. • Litt JZ. Pocketbook of drug eruptions and interactions. The Parthenon Publishing Group Inc. New York, 1999 |
• Vaccine |
• De Keyser F, et al. Clin Exp Rheumatol 2000;18:81-5. • Honl BA, et al. Cutis 1996;57:447-50. • Kaplan B, et al. Isr J Med Sci 1989;25:570-2. |
Information from references 1 through 20. |